What is QbDVision?
QbDVision offers a structured, cloud-based platform designed to unify knowledge of product and manufacturing processes, automating key development workflows throughout the entire product lifecycle. Its Digital CMC platform is specifically engineered for biopharma organizations, aiming to accelerate the transition from R&D to commercial manufacturing. By providing robust CMC knowledge and real-time guidance, QbDVision enables enhanced data-driven decision-making and streamlines complex operational workflows, such as tech transfer, thereby reducing cycle times while ensuring quality and compliance.
How much funding has QbDVision raised?
QbDVision has raised a total of $30.3M across 2 funding rounds:
Angel/Seed
$2.3M
Series A
$28M
Angel/Seed (2019): $2.3M, investors not publicly disclosed
Series A (2025): $28M led by Wanxiang Healthcare Investments (WHI), Northpond Ventures, Hudson Park Capital, S3 Ventures, and Create Health Ventures
Key Investors in QbDVision
Wanxiang Healthcare Investments (WHI)
Wanxiang Healthcare Investments (WHI) is a corporate-backed venture group that focuses on investing in healthcare technologies, particularly in digital health. The firm targets early to growth stage healthcare businesses and typically participates in Series A through Series E funding rounds.
S3 Ventures
S3 Ventures is the largest venture capital firm focused on Texas, based in Austin, and partners with startups across major Texas cities. They invest in sectors such as business technology, digital experiences, and healthcare technology, providing initial investments ranging from $500K to over $10M.
Create Health Ventures
Create Health Ventures is focused on reimagining the healthcare industry by investing in and advising early-stage digital health businesses. The firm seeks to invest in B2B software and tech-enabled services aimed at improving access to care, enhancing patient experiences, and achieving better health outcomes.
What's next for QbDVision?
The substantial enterprise-level funding QbDVision has garnered, particularly the recent strategic investment, positions the company for accelerated growth and market expansion. This capital infusion is expected to fuel further development of its Digital CMC platform, enhance its go-to-market strategies, and solidify its position as a leader in biopharma product lifecycle management. The company's focus on automating development workflows and providing critical CMC knowledge suggests a strategic push towards becoming an indispensable tool for life-changing therapy development.
See full QbDVision company page
